Cellosaurus logo
expasy logo

Cellosaurus IMR-32 (CVCL_0346)

[Text version]
Cell line name IMR-32
Synonyms IMR 32; IMR32; Institute for Medical Research-32; GM03320; GM3320C; GM03320D; AG03320; AG3320
Accession CVCL_0346
Resource Identification Initiative To cite this cell line use: IMR-32 (RRID:CVCL_0346)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Population: Caucasian.
Characteristics: Neuroblastic type (N-type).
Doubling time: 48 hours (PubMed=5459762); ~20 hours (ATCC=CCL-127); ~40-50 hours (DSMZ=ACC-165).
Omics: Array-based CGH.
Omics: Cell surface proteome.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: IMR-92; Note=Occasionally.
Misspelling: IRM-32; Note=Occasionally.
Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
HLA typing Source: PubMed=26589293
Class I
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.56
East Asian, North1.01
East Asian, South0
South Asian3.99
European, North73.7
European, South20.72
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_B0GV (I3.4.2)CVCL_S028 (IMR-32 SimpleCell O-GalNAc)CVCL_A9J0 (IMR-32/CMV-Luc)
CVCL_ZX18 (IMR-32rCARBO1000)CVCL_RR66 (IMR-32rCARBO4000)CVCL_RS61 (IMR-32rCARBO5000)
CVCL_RR67 (IMR-32rCDDP1000)CVCL_RS27 (IMR-32rCDDP500)CVCL_RR68 (IMR-32rDOX20)
CVCL_RS54 (IMR-32rMEL2000)CVCL_RR71 (IMR-32rMEL500)CVCL_RR72 (IMR-32rOXALI4000)
Sex of cell Male
Age at sampling 1Y1M
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; CLS; COG; DSMZ; IZSLER; JCRB; KCLB; PubMed=25877200; PubMed=31581737; PubMed=33460449; RCB; TKG

D16S5398 (ATCC; CCRID; COG; DSMZ; IZSLER; JCRB; PubMed=25877200; PubMed=31581737; PubMed=33460449; RCB; TKG)
8,10 (CLS)
Penta D11,12
Penta E7,15
TH017,9.3 (CCRID; CLS; COG; DSMZ; IZSLER; JCRB_IFO50283; KCLB; PubMed=25877200; PubMed=31581737; PubMed=33460449; RCB; TKG)
7,10 (JCRB_JCRB9050)

Run an STR similarity search on this cell line
Web pages https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/i/cell-lines-detail-508.html

Tumilowicz J.J., Nichols W.W., Cholon J.J., Greene A.E.
Definition of a continuous human cell line derived from neuroblastoma.
Cancer Res. 30:2110-2118(1970)

Biedler J.L.
Chromosome abnormalities in human tumor cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975)

PubMed=62055; DOI=10.1093/jnci/57.3.683
Biedler J.L., Spengler B.A.
A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture.
J. Natl. Cancer Inst. 57:683-695(1976)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=922665; DOI=10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1
Brodeur G.M., Sekhon G., Goldstein M.N.
Chromosomal aberrations in human neuroblastomas.
Cancer 40:2256-2263(1977)

Coriell L.L., Greene A.E., Mulivor R.A.
The human genetic mutant cell repository: list of genetic variants, chromosomal aberrations and normal cell cultures submitted to the repository. 7th edition. October 1980.
(In) Institute for Medical Research (Camden, N.J.) NIH 80-2011; pp.1-254; National Institutes of Health; Bethesda (1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7253718; DOI=10.1016/0047-6374(81)90027-0
Das N.K., Murphy D.G.
The National Institute on Aging repository cell cultures.
Mech. Ageing Dev. 16:1-17(1981)

Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.
Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.
Cancer Res. 42:1331-1336(1982)

PubMed=7139592; DOI=10.1016/0165-4608(82)90105-4
Gilbert F., Balaban G.B., Moorhead P.S., Bianchi D., Schlesinger H.R.
Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines.
Cancer Genet. Cytogenet. 7:33-42(1982)

PubMed=6401685; DOI=10.1007/BF02617989
Halton D.M., Peterson W.D. Jr., Hukku B.
Cell culture quality control by rapid isoenzymatic characterization.
In Vitro 19:16-24(1983)

PubMed=6888561; DOI=10.1038/305245a0
Schwab M., Alitalo K., Klempnauer K.-H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G.M., Goldstein M.N., Trent J.M.
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour.
Nature 305:245-248(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

Bregman M.D., Funk C., Fukushima M.
Inhibition of human melanoma growth by prostaglandin A, D, and J analogues.
Cancer Res. 46:2740-2744(1986)

Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.
Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.
Cancer Res. 49:219-225(1989)

Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y.
Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Cancer Res. 53:5284-5288(1993)

PubMed=8490657; DOI=10.1038/ng0193-62
The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G., Gusella J.F., Bernards A.
Neurofibromatosis type 1 gene mutations in neuroblastoma.
Nat. Genet. 3:62-66(1993)

Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)

Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)

PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4
Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.
The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Cancer Lett. 104:183-192(1996)

Cinatl J. Jr., Hernaiz Driever P., Cinatl J., Ruckert D.G., Gumbel H.O., Rabenau H.F., Kornhuber B., Doerr H.-W.
Increased efficacy of aphidicolin killing of human neuroblastoma cells in vitro by encapsulation in liposomes.
Neoplasma 44:91-95(1997)

PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7
Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.
Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Cancer Genet. Cytogenet. 97:135-142(1997)

PubMed=9516836; DOI=10.1016/S0959-8049(97)00319-5
Van Roy N., Laureys G., Van Gele M., Opdenakker G., Miura R., van der Drift P., Chan A., Versteeg R., Speleman F.
Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes.
Eur. J. Cancer 33:1974-1978(1997)

Thiele C.J.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001)

PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12210830; DOI=10.1002/jnr.10330
Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.
Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.
J. Neurosci. Res. 69:642-652(2002)

Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003)

PubMed=15390183; DOI=10.1002/gcc.20096
Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.
Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
Genes Chromosomes Cancer 41:297-308(2004)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=16524757; DOI=10.1016/j.biocel.2006.01.007
Fry D.G., Dayton B.D., Brodjian S., Ogiela C., Sidorowicz H., Frost L.J., McNally T., Reilly R.M., Collins C.A.
Characterization of a neuronal cell line expressing native human melanin-concentrating hormone receptor 1 (MCHR1).
Int. J. Biochem. Cell Biol. 38:1290-1299(2006)

PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)

PubMed=17974978; DOI=10.1158/0008-5472.CAN-06-4345
Xue C.-Y., Haber M., Flemming C., Marshall G.M., Lock R.B., MacKenzie K.L., Gurova K.V., Norris M.D., Gudkov A.V.
p53 determines multidrug sensitivity of childhood neuroblastoma.
Cancer Res. 67:10351-10360(2007)

PubMed=20655465; DOI=10.1016/j.cell.2010.06.004
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24466371; DOI=10.1593/tlo.13544
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31581737; DOI=10.3390/cells8101194
Povey J.F., Saintas E., Aderemi A.V., Rothweiler F., Zehner R., Dirks W.G., Cinatl J. Jr., Racher A.J., Wass M.N., Smales C.M., Michaelis M.
Intact-cell MALDI-ToF mass spectrometry for the authentication of drug-adapted cancer cell lines.
Cells 8:1194.1-1194.12(2019)

PubMed=33460449; DOI=10.1002/ijc.33474
Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J., Nagel S., Steenpass L., Becker J.
Cross-contamination meets misclassification: awakening of CHP-100 from sleeping beauty sleep -- a reviewed model for Ewing's sarcoma.
Int. J. Cancer 148:2608-2613(2021)

Cell line collections (Providers) ATCC; CCL-127
BCRC; 60014
BCRJ; 0377
CLS; 300148
Coriell; AG03320 - Discontinued
Coriell; GM03320
ECACC; 86041809
ICLC; HTL96021
JCRB; IFO50283
KCB; KCB 2011100YJ
KCLB; 10127
RCB; RCB1895 - Discontinued
TKG; TKG 0207
Cell line databases/resources CLO; CLO_0006948
CLO; CLO_0016777
MCCL; MCC:0000242
CLDB; cl2878
CLDB; cl2879
CLDB; cl2880
CLDB; cl2881
CLDB; cl2882
CLDB; cl2883
CLDB; cl2885
CLDB; cl2886
CLDB; cl2887
CLDB; cl2888
cancercelllines; CVCL_0346
CCRID; 1101HUM-PUMC000282
Cell_Model_Passport; SIDM00226
CGH-DB; 78-1
CGH-DB; 9095-4
DepMap; ACH-000310
DSMZCellDive; ACC-165
Lonza; 971
Anatomy/cell type resources BTO; BTO:0000934
Biological sample resources BioSample; SAMN00808348
BioSample; SAMN03472412
BioSample; SAMN03473082
BioSample; SAMN10988103
CRISP screens repositories BioGRID_ORCS_Cell_line; 637
Chemistry resources ChEMBL-Cells; CHEMBL3307656
ChEMBL-Targets; CHEMBL614585
PharmacoDB; IMR32_659_2019
PubChem_Cell_line; CVCL_0346
Encyclopedic resources Wikidata; Q54897618
Experimental variables resources EFO; EFO_0001195
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
GEO; GSM453632
GEO; GSM563362
GEO; GSM692859
GEO; GSM887162
GEO; GSM888234
GEO; GSM1366406
GEO; GSM1669934
GEO; GSM2371237
GEO; GSM2394364
Polymorphism and mutation databases Cosmic; 688067
Cosmic; 759892
Cosmic; 801746
Cosmic; 920239
Cosmic; 922658
Cosmic; 947702
Cosmic; 1019944
Cosmic; 1037352
Cosmic; 1099149
Cosmic; 1109111
Cosmic; 1237544
Cosmic; 1518066
Cosmic; 1526626
Cosmic; 2058113
Cosmic; 2131590
Cosmic; 2301580
Cosmic; 2393630
Cosmic; 2485944
IARC_TP53; 23585
LiGeA; CCLE_016
Progenetix; CVCL_0346
Proteomic databases PRIDE; PXD000589
Sequence databases EGA; EGAS00001000610
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number45